Display options
Cite
da Silva SD, Marchi FA, Su J, et al. Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. Cancers (Basel). 2021;13(1)doi: 10.3390/cancers13010153.
da Silva, S. D., Marchi, F. A., Su, J., Yang, L., Valverde, L., Hier, J., Bijian, K., Hier, M., Mlynarek, A., Kowalski, L. P., & Alaoui-Jamali, M. A. (2021). Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. Cancers, 13(1), . https://doi.org/10.3390/cancers13010153
da Silva, Sabrina Daniela, et al. "Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype." Cancers vol. 13,1 (2021). doi: https://doi.org/10.3390/cancers13010153
da Silva SD, Marchi FA, Su J, Yang L, Valverde L, Hier J, Bijian K, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. Cancers (Basel). 2021 Jan 05;13(1). doi: 10.3390/cancers13010153. PMID: 33466385; PMCID: PMC7795342.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jan 05;13(1). doi: 10.3390/cancers13010153.

Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype.

Cancers

Sabrina Daniela da Silva, Fabio Albuquerque Marchi, Jie Su, Long Yang, Ludmila Valverde, Jessica Hier, Krikor Bijian, Michael Hier, Alex Mlynarek, Luiz Paulo Kowalski, Moulay A Alaoui-Jamali

Affiliations

  1. Department of Otolaryngology Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
  2. Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
  3. Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Cancer Center and National Institute of Science and Technology on Oncogenomics (INCITO), São Paulo 01509-010, Brazil.
  4. School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

PMID: 33466385 PMCID: PMC7795342 DOI: 10.3390/cancers13010153

Abstract

Invasive oral squamous cell carcinoma (OSCC) is often ulcerated and heavily infiltrated by pro-inflammatory cells. We conducted a genome-wide profiling of tissues from OSCC patients (early versus advanced stages) with 10 years follow-up. Co-amplification and co-overexpression of

Keywords: CSF1; EMT; TWIST1; genomic; metastasis; oral squamous cell carcinoma; tumor invasion; tumor-associated macrophages

References

  1. Front Pharmacol. 2012 Jul 30;3:149 - PubMed
  2. Nat Med. 1998 Jul;4(7):844-7 - PubMed
  3. Cell. 2004 Aug 6;118(3):277-9 - PubMed
  4. Mol Cancer. 2011 Sep 22;10:117 - PubMed
  5. Lancet. 2019 Jan 12;393(10167):156-167 - PubMed
  6. Cancer Res. 2014 Mar 15;74(6):1694-704 - PubMed
  7. Clin Cancer Res. 1998 Aug;4(8):1851-6 - PubMed
  8. N Engl J Med. 2010 Mar 11;362(10):875-85 - PubMed
  9. J Natl Cancer Inst. 2014 May 29;106(6):dju124 - PubMed
  10. J Immunol. 2010 Jan 15;184(2):702-12 - PubMed
  11. Curr Opin Oncol. 2009 May;21(3):194-200 - PubMed
  12. Br J Cancer. 2014 May 13;110(10):2560-8 - PubMed
  13. Oncogene. 2015 May 21;34(21):2721-31 - PubMed
  14. Cancer. 2014 Feb 1;120(3):352-62 - PubMed
  15. Cancer Res. 2014 Sep 15;74(18):5057-69 - PubMed
  16. Cell. 2010 Apr 2;141(1):39-51 - PubMed
  17. Immunol Lett. 2009 Apr 27;123(2):97-102 - PubMed
  18. Oncogene. 2002 Apr 18;21(17):2634-40 - PubMed
  19. J Pathol. 2013 Jul;230(3):310-21 - PubMed
  20. Cancer Res. 2010 Jun 15;70(12):4840-9 - PubMed
  21. Am J Pathol. 2011 Oct;179(4):1827-38 - PubMed
  22. J Otolaryngol. 2006 Jun;35(3):157-66 - PubMed
  23. Cancer Res. 2011 Feb 15;71(4):1325-33 - PubMed
  24. Ann N Y Acad Sci. 2004 Apr;1014:58-66 - PubMed
  25. Neoplasia. 2006 Nov;8(11):925-32 - PubMed
  26. Stem Cells. 1994;12 Suppl 1:15-24; discussion 25 - PubMed
  27. PLoS One. 2011 Mar 28;6(3):e18023 - PubMed
  28. Clin Cancer Res. 2014 Dec 1;20(23):6212-22 - PubMed
  29. Oncogene. 2014 Aug 21;33(34):4359-64 - PubMed
  30. Curr Opin Immunol. 2006 Feb;18(1):39-48 - PubMed
  31. Oral Oncol. 2019 Jan;88:131-136 - PubMed
  32. PLoS One. 2011;6(12):e29758 - PubMed
  33. Cancer Res. 2013 Jan 15;73(2):662-71 - PubMed
  34. Clin Transl Med. 2020 Nov;10(7):e209 - PubMed
  35. Cancer Res. 2010 Feb 15;70(4):1323-33 - PubMed
  36. J Exp Med. 2010 Oct 25;207(11):2421-37 - PubMed
  37. Lab Invest. 2014 Apr;94(4):371-81 - PubMed
  38. Oncotarget. 2015 Sep 8;6(26):21950-63 - PubMed
  39. Cancer Microenviron. 2014 Dec;7(3):153-60 - PubMed
  40. Cancer Lett. 2013 May 10;332(1):3-10 - PubMed
  41. Nucleic Acids Res. 2001 May 1;29(9):e45 - PubMed
  42. Arch Otolaryngol Head Neck Surg. 2007 Sep;133(9):910-8 - PubMed
  43. BMC Cancer. 2012 Jan 24;12:35 - PubMed
  44. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  45. Clin Cancer Res. 2015 Feb 15;21(4):687-92 - PubMed
  46. Cancer Res. 2007 Oct 1;67(19):9066-76 - PubMed
  47. EMBO Mol Med. 2014 Sep 11;6(10):1279-93 - PubMed
  48. Cancer Res. 2009 Dec 15;69(24):9498-506 - PubMed
  49. Development. 2001 Aug;128(16):3145-59 - PubMed
  50. Oncogene. 2012 Mar 15;31(11):1459-67 - PubMed
  51. PLoS One. 2010 Oct 26;5(10):e13587 - PubMed
  52. BMC Mol Biol. 2010 Sep 21;11:74 - PubMed

Publication Types

Grant support